Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Sanam Loghavi, MD
Articles by Sanam Loghavi, MD
Panel Discusses the Future of MPN Treatment
Ruben Mesa, MD
Uncategorized
|
June 7, 2024
In the last segment of the roundtable series, the panel discusses the future of myelofibrosis treatment.
View More
Which JAK Inhibitors Are Clinicians Prescribing for Myelofibrosis?
Ruben Mesa, MD
Uncategorized
|
July 2, 2024
The panel discusses the four JAK inhibitors approved by the FDA: ruxolitinib, fedratinib, pacritinib, and momelotinib.
View More
When Should Clinicians Treat Myelofibrosis With Momelotinib?
Ruben Mesa, MD
The HemOnc Pulse Live
|
June 7, 2024
In the sixth segment of the roundtable series, the panel discusses momelotinib and pacritinib treatment in myelofibrosis.
View More
What Setting Should Clinicians Use Fedratinib to Treat Patients With Myelofibrosis?
Ruben Mesa, MD
The HemOnc Pulse Live
|
June 7, 2024
The panel discusses fedratinib for myelofibrosis and whether it's used in the frontline or second line setting.
View More
What Drives Frontline Treatment Decisions in Patients With Myelofibrosis?
Ruben Mesa, MD
The HemOnc Pulse Live
|
June 7, 2024
In the fourth segment of the roundtable series, the panel discusses frontline ruxolitinib treatment for myelofibrosis.
View More
MPN Roundtable: Which Patients Go Directly to Transplant?
Ruben Mesa, MD
The HemOnc Pulse Live
|
June 7, 2024
This roundtable session addresses which patients go directly to transplant, when to observe patients, and more.
View More
‘The HemOnc Pulse’ Live 2024: Is it Time for New Endpoints in MPN?
Naveen Pemmaraju, MD
The HemOnc Pulse Live
|
July 26, 2024
The panel considered whether it’s time for new response criteria in myelofibrosis such as anemia improvement.
Listen Now
‘The HemOnc Pulse’ Live: What Are the Unanswered Questions in ALL?
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse Live
|
May 23, 2024
The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.
Listen Now
Panel Discusses Key Diagnostic Standards for Myelofibrosis
Ruben Mesa, MD
Video Insights
|
June 7, 2024
In the first segment of the roundtable series, the panel discusses how myelofibrosis is diagnosed and assessed.
View More
How Are Prognostic Scores Factored into Myelofibrosis Frontline Therapy Planning?
Ruben Mesa, MD
Video Insights
|
June 7, 2024
Dr. Naveen Pemmaraju discusses the history of prognostic scoring systems and how they factor into frontline therapy planning.
View More
Unanswered Questions in MDS at ‘The HemOnc Pulse’ Live 2024 in Chicago
Chadi Nabhan, MD, MBA, FACP
Myelodysplastic Syndromes
|
May 13, 2024
The panel mainly focused on how to define and classify MDS and CHIP, as well as how to treat low- and high-risk MDS.
Listen Now
'The HemOnc Pulse' Live 2024 in Chicago: AML Unanswered Questions
Chadi Nabhan, MD, MBA, FACP
The HemOnc Pulse Live
|
May 8, 2024
Live in Chicago, this podcast episode features a panel discussion on unanswered questions in AML.
Listen Now
Sanam Loghavi, MD: 'The HemOnc Pulse' Live Sheds a Spotlight on Hematopathology
Sanam Loghavi, MD
The HemOnc Pulse Live
|
May 13, 2024
“I’m grateful to shed a spotlight on hematopathology and what we contribute to these patients," Dr. Loghavi said.
View More
WHO Experts on MDS Take Over The HemOnc Pulse at SOHO 2023
Chadi Nabhan, MD, MBA, FACP
Myelodysplastic Syndromes
|
September 14, 2023
Joseph Khoury, MD; Sanam Loghavi, MD; and Chadi Nabhan, MD, MBA, FACP, discuss the MDS classification systems.
View More